Announcements Call for applications by The Migration Health South Asia Network for skill & capacity development training workshop to be held in 6-9 April 2020   |   Open Letter: Stop the war on Syria’s hospitals

The author defends

Chandra M Gulhati

DOI: 10.20529/IJME.2004.036


‘How many people know that eight patients in Hyderabad who were administered recombinant streptokinase to test its efficacy and safety have died? According to the Genetic Engineering Approval Committee (GEAC), the trial was being conducted by the drug’s manufacturer Shantha Biotechnics without taking clearance. Not surprisingly, the Company denies the allegation claiming that it had taken permission from the DCGI.

Full Text





There are currently no refbacks.

Article Views

PDF Downloads

Click here to support US